Study Name:
Placebo-controlled study of concurrent chemoradiation therapy with Pembrolizumab followed by Pembrolizumab and Olaparib in newly diagnosed, treatment-naïve limited-stage small cell lung cancer (LS-SCLC)
Targeted Disease(s):
Lung Cancer
Purpose of Study:
This clinical trial is trying to find out if a combination of study drugs can help stop or slow down this type of cancer.Study Dates:
December 8, 2020 - October 28, 2027
Study Location:
Nationwide
Funding Source:
Merck & Co., Inc.
ClinicalTrails.gov Identifier:
NCT04624204
